Kimino Fujimura

Kimino Fujimura

Auto-generated profile, based on publicly available information

Kimino Fujimura

F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2016 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
KFKimino Fujimura
Kimino Fujimura
TMTakayuki Mitsuhashi
Takayuki Mitsuhashi
SSShinsuke Shibata
Shinsuke Shibata
SSSachiko Shimozato
Sachiko Shimozato
TTTakao Takahashi
Takao Takahashi
Valproic acid (VPA), a widely used antiepileptic drug, is an inhibitor of histone deacetylases, which epigenetically modify cell proliferation/differentiation in developing tissues. A series of recent clinical studies in humans reported that VPA exposurein uteroimpaired histogenesis and the development of the central nervous system, leading to increased risks of congenital malformation and the impairment of higher brain functions in children. In the present study conducted in mice, we report that VPA exposurein utero(1) increases the amount of acetylated histone proteins, (2) alters the expression of G1-phase regulatory proteins, (3) inhibits the cell cycle exit of neural progenitor cells during the early stage of neocortical histogenesis, and (4) increases the production of projection neurons distributed in the superficial neocortical layers in embryonic brains. Together, our findings show that VPA exposurein uteroalters proliferation/differentiation characteristics of neural progenitor cells and hence leads to the neocortical dysgenesis.SIGNIFICANCE STATEMENTThis study provides new insight into the mechanisms of how an alteredin uteroenvironment, such as drug exposure, affects the generation of neurons prenatally. The antiepileptic drug valproic acid (VPA) is a good target molecule asin uteroexposure to VPA has been repeatedly reported to increase the risk of nervous system malformations and to impair higher brain functions in children. We show that VPA decreases the probability of differentiation of the neural progenitor cells (NPCs) in mice, resulting in an abnormally increased number of projection neurons in the superficial layers of the neocortex. Further, we suggest that histone deacetylase inhibition by VPA may be involved in the dysregulation of proliferation/differentiation characteristics of NPCs.

24 January 2022 in Neonatology
Verified
Journal Article
Open access
PDF file
SASaima Ahmed
Saima Ahmed
OOOludare Adedayo Odumade
Oludare Adedayo Odumade
PZPatrick van Zalm
Patrick van Zalm
KSKinga K. Smolen
Kinga K. Smolen
KFKimino Fujimura
Kimino Fujimura
HSHanno Steen
Hanno Steen
Introduction: Current techniques to diagnose and/or monitor critically ill neonates with bronchopulmonary dysplasia (BPD) require invasive sampling of body fluids, which is suboptimal in these frail neonates. We tested our hypothesis that it is feasible to use noninvasively collected urine samples for proteomics from extremely low gestational age newborns (ELGANs) at risk for BPD to confirm previously identified proteins and biomarkers associated with BPD. Methods: We developed a robust high-throughput urine proteomics methodology that requires only 50 μL of urine. We utilized the methodology with a proof-of-concept study validating proteins previously identified in invasively collected sample types such as blood and/or tracheal aspirates on urine collected within 72 h of birth from ELGANs (gestational age [26 ± 1.2] weeks) who were admitted to a single Neonatal Intensive Care Unit (NICU), half of whom eventually developed BPD (n = 21), while the other half served as controls (n = 21). Results: Our high-throughput urine proteomics approach clearly identified several BPD-associated changes in the urine proteome recapitulating expected blood proteome changes, and several urinary proteins predicted BPD risk. Interestingly, 16 of the identified urinary proteins are known targets of drugs approved by the Food and Drug Administration. Conclusion: In addition to validating numerous proteins, previously found in invasively collected blood, tracheal aspirate, and bronchoalveolar lavage, that have been implicated in BPD pathophysiology, urine proteomics also suggested novel potential therapeutic targets. Ease of access to urine could allow for sequential proteomic evaluations for longitudinal monitoring of disease progression and impact of therapeutic intervention in future studies.

19 May 2023 in iScience
Verified
Journal Article
Open access
KFKimino Fujimura
Kimino Fujimura
AGAmanda J. Guise
Amanda J. Guise
TNTojo Nakayama
Tojo Nakayama
CSChristoph N. Schlaffner
Christoph N. Schlaffner
AMAnais Meziani
Anais Meziani
JSJudith A. Steen
Judith A. Steen
Characterizing perturbation of molecular pathways in congenital Zika virus (ZIKV) infection is critical for improved therapeutic approaches. Leveraging integrative systems biology, proteomics, and RNA-seq, we analyzed embryonic brain tissues from an immunocompetent, wild-type congenital ZIKV infection mouse model. ZIKV induced a robust immune response accompanied by the downregulation of critical neurodevelopmental gene programs. We identified a negative correlation between ZIKV polyprotein abundance and host cell cycle-inducing proteins. We further captured the downregulation of genes/proteins, many of which are known to be causative for human microcephaly, including Eomesodermin/T-box Brain Protein 2 (EOMES/TBR2) and Neuronal Differentiation 2 (NEUROD2). Disturbances of distinct molecular pathways in neural progenitors and post-mitotic neurons may contribute to complex brain phenotype of congenital ZIKV infection. Overall, this report on protein- and transcript-level dynamics enhances understanding of the ZIKV immunopathological landscape through characterization of fetal immune response in the developing brain.

18 October 2022 in Current Medical Research and Opinion
Verified
Journal Article
Open access
SFShinsuke Fujioka
Shinsuke Fujioka
Takayasu MishimaTakayasu Mishima
Takayasu Mishima
TYToru Yamazaki
Toru Yamazaki
MBMagdalena Bebrysz
Magdalena Bebrysz
MNMariko Nomoto
Mariko Nomoto
YTYoshio Tsuboi
Yoshio Tsuboi
This study measures the relative preference for attributes of device-aided therapies (DATs) for advanced Parkinson’s Disease (PD) from the perspective of Japanese neurologists.Attributes and levels...

12 April 2023 in Developmental Neuroscience
Verified
Journal Article
Open access
PDF file
TMTakayuki Mitsuhashi
Takayuki Mitsuhashi
SHSatoko Hattori
Satoko Hattori
KFKimino Fujimura
Kimino Fujimura
SSShinsuke Shibata
Shinsuke Shibata
TMTsuyoshi Miyakawa
Tsuyoshi Miyakawa
TTTakao Takahashi
Takao Takahashi
Valproic acid (VPA) is an antiepileptic drug that inhibits the epileptic activity of neurons mainly by inhibiting sodium channels and GABA transaminase. VPA is also known to inhibit histone deacetylases, which epigenetically modify the cell proliferation/differentiation characteristics of stem/progenitor cells within developing tissues. Recent clinical studies in humans have indicated that VPA exposure in utero increases the risk of autistic features and intellectual disabilities in offspring; we have previously reported that low-dose VPA exposure in utero throughout pregnancy increases the production of projection neurons from neuronal stem/progenitor cells that are distributed in the superficial neocortical layers of the fetal brain. In the present study, we found that in utero VPA-exposed mice exhibited abnormal social interaction, changes in cognitive function, hypersensitivity to pain/heat, and impaired locomotor activity, all of which are characteristic symptoms of autism spectrum disorder in humans. Taken together, our findings indicate that VPA exposure in utero throughout pregnancy alters higher brain function and predisposes individuals to phenotypes that resemble autism and intellectual disability. Furthermore, these symptoms are likely to be due to neocortical dysgenesis that was caused by an increased number of projection neurons in specific layers of the neocortex.